Sarepta Therapeutics Inc. reported preliminary financial results for the fourth quarter (Q4) and full year (FY) 2025. The company posted total net product revenue of USD 369.6 million for Q4 and USD 1.86 billion for FY 2025. ELEVIDYS net product revenue reached USD 110.4 million in Q4 and USD 898.7 million for the full year. Sarepta’s PMO franchise generated USD 259.2 million in net product revenue for Q4 and USD 965.6 million for FY 2025. As of December 31, 2025, Sarepta Therapeutics Inc. reported a preliminary cash, cash equivalents, restricted cash and investments balance of approximately USD 953.8 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sarepta Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-010116), on January 12, 2026, and is solely responsible for the information contained therein.